Notice: ASA extends its thoughts and condolences to those affected by the disaster in Oklahoma. Donations to help aid this relief can be made through the American Red Cross website.

>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS
>

FDA MEDWATCH ALERTS

RSS

May 20, 2013

All Sterile Drug Products Made and Distributed By NuVision Pharmacy Dallas Facility: Recall - Lack Of Sterility Assurance

Summary:

All Sterile Drug Products Made and Distributed By NuVision Pharmacy Dallas Facility

May 14, 2013

Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses

Summary:

Zolpidem Containing Products Drug Safety Communication

May 09, 2013

The Compounding Shop: FDA News Release - Lack of Sterility Assurance of Drug Products

Summary:

The Compounding Shop FDA News Release Lack of Sterility

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-13CE

... Read more »

Single Copies, Member Price: $360

Congressional Researchers Question IPAB

Tuesday, December 21, 2010

A recently obtained report authored by the non-partisan Congressional Research Service (CRS) raises questions about the Independent Payment Advisory Board (IPAB), a draconian Medicare cost-cutting mechanism created by the new health care reform law, the Patient Protection and Affordable Care Act (PPACA).

The reform law created the IPAB as a novel and aggressive mechanism to “reduce the per capita rate of growth in Medicare spending.” The Board, composed of 15 members appointed by the President, is charged with developing proposals to maintain Medicare spending below a targeted per capita growth rate.  In a process reminiscent of that used for the Defense Base Realignment and Closure (BRAC) Commission, the Board’s proposals receive special expedited and protected consideration by Congress.  The process spelled out in the statute creates a number of barriers that inhibit Congress’ ability to reject or defeat any proposed Medicare cuts.    

The CRS report highlights that the IPAB provision may be open to legal challenges because the law shifts the “balance of power to the executive branch and away from Congress.” The report also questions how the IPAB procedures will impact House and Senate parliamentary procedures and the constitutional rights of both chambers. 

Currently, the constitutionality of the Board is being challenged in federal district court in Arizona by the Goldwater Institute.

ASA opposed the inclusion of IPAB during the health system reform debate and currently supports repeal of the provision creating the Board.         

« Back to Washington Alerts